GWM
IBRX icon

Geneos Wealth Management’s ImmunityBio IBRX Stock Holding History

Geneos Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4K Hold
5,754
– – ﹤0.01% 1458
2026
Q1 		$44.1K Buy
5,754
+4,907
+579% +$33.6K ﹤0.01% 1480
2025
Q4 		$1.68K Hold
847
– – ﹤0.01% 2345
2025
Q3 		$2.08K Hold
847
– – ﹤0.01% 2314
2025
Q2 		$2.24K Hold
847
– – ﹤0.01% 2785
2025
Q1 		$2.55K Sell
847
-1,000
-54% -$3.03K ﹤0.01% 2700
2024
Q4 		$4.73K Buy
1,847
+1,000
+118% +$4.17K ﹤0.01% 2351
2024
Q3 		$3.15K Hold
847
– – ﹤0.01% 2190
2024
Q2 		$5.35K Buy
+847
New +$5.58K ﹤0.01% 1706

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geneos Wealth Management's IBRX Position: Q2 2026 in Review

Geneos Wealth Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 5,754 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Geneos Wealth Management first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Geneos Wealth Management held 5,754 shares of ImmunityBio worth $50.4K as of Q2 2026.
  • Geneos Wealth Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1458 holding.
  • Geneos Wealth Management first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.